Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

GEH 200520/GEH 200521

Next Previous
X
Search
Drug Profile

GEH 200520/GEH 200521

Alternative Names: 18F-CD8 PET; [18F]GEH200521; GEH-200520/GEH-200521; GEH200520 Injection /GEH200521 (18F) Injection

Latest Information Update: 12 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator GE Healthcare
  • Class Diagnostic agents; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I Solid tumours

Most Recent Events

  • 02 Jul 2024 Phase-I clinical trials in Solid tumours (In volunteers, Diagnosis) in USA (Parenteral) (NCT06398730)
  • 03 May 2024 GE Healthcare plans a phase I trial pharmacokinetics trial (In volunteers, Diagnosis) (Parenteral, Injection) in May 2024 (NCT06398730)
  • 19 Jun 2023 Phase-I clinical trials in Solid tumours (Diagnosis) in Netherlands (Parenteral) (NCT05629689)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top